Abstract:A diverse group of proteins, the activities of which are precisely orchestrated during mitosis, have emerged as targets for cancer therapeutics; these include the Aurora kinases (AKs), Polo-like kinases (PLKs), and the kinesin spindle protein (KSP). KSP is essential for the proper separation of spindle poles during mitosis. Agents that target KSP selectively act on cells undergoing cell division, which means that KSP inhibitors are mitosis-specific drugs, and have demonstrated remarkable activities in vitro. However, a significant obstacle to the success of KSP inhibitors is that these compounds, with tremendous efficacy in vitro, have demonstrated little or even no antitumor activity in vivo. Accumulated data suggest that a combination of KSP inhibitors with various cytostatic drugs will result in a more powerful tumor-killing effect than monotherapy. Combination therapies might predominate and represent the next frontier in the discovery research of KSP inhibitors as potential anticancer drugs. Few published studies have reviewed combination therapy using KSP inhibitors. Herein we provide a comprehensive review of the literature on KSP inhibitor monotherapy and therapeutic combinations. The current state and problems are also discussed.

Design, synthesis and biological evaluation of novel KSP inhibitors

[Synthesis and Antitumor Activity of Novel Tetrahydro-Beta-carboline Derivatives As KSP Inhibitors].

De Novo Design, Synthesis and Biological Evaluation of 1,4-Dihydroquinolin-4-ones and 1,2,3,4-Tetrahydroquinazolin-4-ones As Potent Kinesin Spindle Protein (KSP) Inhibitors

Synthesis and biological evaluation of tetrahydro-β-carline derivatives

Synthesis, Biological Evaluation and Molecular Docking Studies of Flavone and Isoflavone Derivatives As a Novel Class of KSP (kinesin Spindle Protein) Inhibitors

Kinesin Spindle Protein Inhibitors As Anticancer Agents

Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.

Progress on Kinesin Spindle Protein Inhibitors As Anti-Cancer Agents

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP

Discovery of tetrahydro-β-carbolines as inhibitors of the mitotic kinesin KSP

Progress of Kinesin Spindle Protein Inhibitors

Kinesin Spindle Protein Inhibitors in Cancer: a Patent Review (2008 – Present)

Kinesin Spindle Protein (KSP) Inhibitors in Combination with Chemotherapeutic Agents for Cancer Therapy

Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2<i>S</i>)-4-(2,5-Difluorophenyl)-<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-<i>N</i>-methyl-2-phenyl-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer

Progress in ATP-competitive Kinesin Spindle Protein Inhibitors as Anticancer Agents

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Design, Synthesis and Antitumor Evaluation of a New Series of N-substituted-thiourea Derivatives

Design, Synthesis and Bioevaluation of Dihydropyrazolo[3,4-B]pyridine and Benzo[4,5]imidazo[1,2-A]pyrimidine Compounds As Dual KSP and Aurora-A Kinase Inhibitors for Anti-Cancer Agents.

Kinesin Spindle Protein (KSP) Inhibitors. Part 6: Design and Synthesis of 3,5-Diaryl-4,5-dihydropyrazole Amides As Potent Inhibitors of the Mitotic Kinesin KSP.

Discovery of Novel KSP-targeting PROTACs with Potent Antitumor Effects in Vitro and in Vivo